Source: Health Products Regulatory Authority (IE) Revision Year: 2021 Publisher: Ferring Ireland Ltd, United Drug House, Magna Drive, Magna Business Park, Citywest Road, Dublin 24, Ireland
Pentasa Sachet 2g prolonged-release granules.
| Pharmaceutical Form |
|---|
|
Prolonged release granules. White-grey to pale white-brown granules. |
Each sachet contains mesalazine 2 g.
For a full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Mesalazine |
Mesalazine is an aminosalicylate. The mechanism of action of mesalazine is not fully understood, but appears to have a topical anti-inflammatory effect on the colonic epithelial cells. Mucosal production of arachidonic acid metabolites, both through the cyclooxygenase and lipoxygenase pathways, is increased in patients with chronic inflammatory bowel disease, and it is possible that mesalazine diminishes inflammation by blocking cyclooxygenase and inhibiting prostaglandin production in the colon. |
| List of Excipients |
|---|
|
Ethylcellulose |
Polyester/Aluminium/LD polyethylene sachet.
Pack sizes: 1 × 60, 1 × 120, 1 × 10 sachets.
Not all pack sizes may be marketed.
Ferring Ireland Ltd, United Drug House, Magna Drive, Magna Business Park, Citywest Road, Dublin 24, Ireland
PA1009/006/006
Date of first authorisation: 19th December 2007
Date of last renewal: 28th February 2011
| Drug | Countries | |
|---|---|---|
| PENTASA | Austria, Australia, Brazil, Canada, Cyprus, Germany, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Japan, Lithuania, Malta, Mexico, Nigeria, Netherlands, New Zealand, Poland, Romania, Singapore, Tunisia, Turkey, United Kingdom, United States, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
